| Drug Name |
Blinatumomab |
| Drug ID |
BADD_D00282 |
| Description |
Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. A full treatment regimen consisting of two cycles of four weeks each, is priced at $178 000 USD. Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. |
| Indications and Usage |
Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). |
| Marketing Status |
approved; investigational |
| ATC Code |
L01FX07 |
| DrugBank ID |
DB09052
|
| KEGG ID |
D09325
|
| MeSH ID |
C510808
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0K4RK
|
| NDC Product Code |
55513-160; 17504-0011 |
| UNII |
4FR53SIF3A
|
| Synonyms |
blinatumomab | MT-103 antibody | antibody MT-103 | Blincyto | MEDI-538 |
